Alder Biopharmaceuticals Inc. Secures $11,100,000 Series A Round
-
Feed Type
-
Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=c341ecdc-1098-42f6-8008-633e7b7ed0d1&Preview=1 -
Date
8/15/2005 -
Company Name
Alder Biopharmaceuticals Inc. -
Mailing Address
11804 North Creek Parkway South Bothell, WA 98011 -
Company Description
Alder Biopharmaceuticals uniquely identifies, develops, and manufactures novel antibody therapeutics to alleviate human suffering in the autoimmune and inflammatory disease areas. Alder’s management team combines decades of industry experience with a proven track record for identifying and developing novel antibody therapeutics. -
Website
http://www.alderbio.com -
Transaction Type
Venture Equity -
Transaction Amount
$11,100,000 -
Transaction Round
Series A -
Proceeds Purposes
This funding will allow us to develop our lead antibody therapeutic, broaden our product pipeline, and build on our proprietary antibody discovery and manufacturing technologies. -
M&A Terms
-
Venture Investor
Sevin Rosen Funds -
Venture Investor
Ventures West -
Venture Investor
WRF Capital
